Skip to main content

Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial.

Frontiers in oncology

Authors: Susanne Wiegand, Gunnar Wichmann, Jeannette Vogt, Kathrin Vogel, Annegret Franke, Thomas Kuhnt, Florian Lordick, Anne-Marie Scheuble, Peter Hambsch, Peter Brossart, Franz Georg Bauernfeind, Holger Kaftan, Georg Maschmeyer, Matthias Paland, Marc Münter, Victor Lewitzki, Nicole Rotter, Carmen Stromberger, Marcus Beck, Steffen Dommerich, Thomas Christoph Gauler, Gunnar Hapke, Orlando Guntinas-Lichius, Ursula Schröder, Martin Görner, Matthias G Hautmann, Felix Steger, Bálint Tamaskovics, Anett Schmiedeknecht, Andreas Dietz

Most of the patients with head and neck squamous cell carcinoma (HNSCC) are diagnosed with locally advanced disease. Standards of care for curative-intent treatment of this patient group are either surgery and adjuvant radio(chemo)therapy (aRCT) or definitive chemoradiation. Despite these treatments, especially pathologically intermediate and high-risk HNSCC often recur. The ADRISK trial investigates in locally advanced HNSCC and intermediate and high risk after up-front surgery if the addition of pembrolizumab to aRCT with cisplatin improves event-free sur-vival compared to aRCT alone. ADRISK is a prospective, randomized controlled investiga-tor-initiated (IIT)-phase II multicenter trial within the German Interdisciplinary Study Group of German Cancer Society (IAG-KHT). Patients with primary resectable stage III and IV HNSCC of the oral cavity, oropharynx, hypopharynx and larynx with pathologic high (R1, extracapsular nodal extension) or intermediate risk (R0 <5 mm; N≥2) after surgery will be eligible. Two hun-dred forty patients will be randomly assigned (1:1) to either standard aRCT with cisplatin (standard arm) or aRCT with cisplatin + pembrolizumab (200 mg iv, in 3-week cycle, max. 12 months) (interventional arm). Endpoints are event-free and overall survival. Recruitment started in August 2018 and is ongoing.

Copyright © 2023 Wiegand, Wichmann, Vogt, Vogel, Franke, Kuhnt, Lordick, Scheuble, Hambsch, Brossart, Bauernfeind, Kaftan, Maschmeyer, Paland, Münter, Lewitzki, Rotter, Stromberger, Beck, Dommerich, Gauler, Hapke, Guntinas-Lichius, Schröder, Görner, Hautmann, Steger, Tamaskovics, Schmiedeknecht and Dietz.

PMID: 37025596

Participating cluster members